PROK Stock Analysis: Buy, Sell, or Hold?
PROK - ProKidney Corp. Class A Ordinary Shares
$1.41
-0.02 (-1.40%)
▼
5d:
+6.02%
30d:
-16.07%
90d:
-8.44%
BUY
MODERATE Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 09, 2026
16d
Get Alerted When PROK Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: PROK shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: PROK shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: PROK is currently trading at $1.41, which is considered oversold relative to its 30-day fair value range of $1.51 to $1.79.
Technical Outlook: Technically, PROK is in a uptrend. Immediate support is located at $1.30, while resistance sits at $1.74.
Market Sentiment: PROK scores 66/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $6.90 (+389.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, PROK is in a uptrend. Immediate support is located at $1.30, while resistance sits at $1.74.
Market Sentiment: PROK scores 66/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $6.90 (+389.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.51 -
$1.79
Company Quality Score
68/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
94.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (66/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 389.4% below Wall St target ($6.90)
- BULLISH: Bottoming setup score 66/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$1.51 -
$1.79
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.31
Resistance Level
$1.74
Current Trend
Uptrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.32
Wall Street Target
$6.90
(+389.4%)
Revenue Growth (YoY)
-32.1%
Share & Embed Analysis
Last updated: October 23, 2026 6:47 PM ET
Data refreshes hourly during market hours. Next update: 7:47 PM
Data refreshes hourly during market hours. Next update: 7:47 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PROK showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RVMD
Revolution Medicines Inc |
STRONG BUY
24 analysts |
$258 | 61 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
21 analysts |
$95 | 50 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$72 | 48 HOLD |
|
JANX
Janux Therapeutics Inc |
STRONG BUY
18 analysts |
$36 | 43 HOLD |
|
SNDX
Syndax Pharmaceuticals I… |
STRONG BUY
12 analysts |
$37 | 59 HOLD |
